Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119110 | 0.88 | KMT2A (0.53) | EPHX2KMT2AHIF1A | |
| SCHEMBL29679265 | 0.88 | KMT2A (0.53) | EPHX2KMT2AHIF1A | |
| SCHEMBL29618948 | 0.88 | KMT2A (0.53) | EPHX2KMT2AHIF1A | |
| SCHEMBL5551698 | 0.86 | KMT2A (0.49) | EPHX2KMT2A | |
| SCHEMBL14452747 | 0.85 | EPHX2 (0.48) | EPHX2KMT2A | |
| SCHEMBL20530670 | 0.85 | EPHX2 (0.46) | EPHX2KMT2A | |
| SCHEMBL15372956 | 0.85 | EPHX2 (0.52) | EPHX2KMT2A | |
| SCHEMBL19633130 | 0.83 | EPHX2 (0.66) | EPHX2KMT2AROCK2ROCK1 | |
| SCHEMBL18688054 | 0.83 | EPHX2 (0.53) | EPHX2KMT2A | |
| SCHEMBL694225 | 0.83 | EPHX2 (0.56) | EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263540-A1 | SMALL-MOLECULE INHIBITORS OF PROTEIN SYNTHESIS INACTIVATING TOXINS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-10-27 | — | — | US | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-20100261760-A1 | EP2 Receptor Agonists | ASTERAND UK LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803841-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-7662839-B2 | EP2 receptor agonists | ASTERAND UK LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED | 2009-12-03 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7326732-B2 | EP2 receptor agonists | PHARMAGENE LABORATORIES LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| EP-1723132-A1 | EP2 RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | ASTERAND, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005080367-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298899-A1 | EP2 RECEPTOR AGONISTS | PTGER2, PTGER1, TBXA2R | EPHX2 125/4885KMT2A 2036/4885LOXL2 401/4885 |
| US-20080119526-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders; e.g. {4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl}-acetic acid | PTGER3, PTGER4, PTGES3 | EPHX2 939/4885KMT2A 4712/4885LOXL2 1371/4885 |
| US-20100261760-A1 | EP2 Receptor Agonists | PTGER2, PTGER1, TBXA2R | EPHX2 125/4885KMT2A 2036/4885LOXL2 401/4885 |
| US-20050256170-A1 | EP receptor (for which the endogenous ligand is prostaglandin E2, PGE2); e.g. (4-[(5-Phenyl-furan-2-carbonyl)-amino]-phenyl)-acetic acid or 5-Phenyl-furan-2-carboxylic acid [3-(1H-tetrazol-5-yl)-phenyl]-amide; dysmenorrhoea, preterm labour, glaucoma, immune disorders, inflammatory disorders | PTGER3, PTGER1, PTGER4 | EPHX2 765/4885KMT2A 4755/4885LOXL2 1265/4885 |
| US-20110263540-A1 | SMALL-MOLECULE INHIBITORS OF PROTEIN SYNTHESIS INACTIVATING TOXINS | MRPS27, MRPS22, MRPS23 | EPHX2 4095/4885KMT2A 2997/4885LOXL2 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.